TD Cowen analyst Marc Frahm has maintained their bullish stance on CRDF stock, giving a Buy rating on April 29.
Marc Frahm’s rating is based on several promising developments in Cardiff Oncology’s ongoing clinical trials. The company has completed enrollment in the CRDF-004 trial, which evaluates the efficacy of onvansertib in combination with other treatments for first-line RAS+ metastatic colorectal cancer. The trial aims to demonstrate a significant improvement in objective response rate (ORR), with interim data already showing promising results.
The interim results indicated a notable ORR benefit in the onvansertib arm compared to the standard of care, and a clear dose response was observed. This success positions Cardiff to potentially pursue accelerated approval strategies similar to those used by other successful trials. With a substantial market opportunity and high unmet medical need, these factors contribute to the optimism reflected in Frahm’s Buy rating.